Cancer and Leukemia Group B 89803 ( Alliance ) randomly assigned 1,264 patients with stage III colon cancer to postoperative weekly adjuvant bolus 5-fluorouracil/leucovorin ( FU/LV ) or irinotecan + FU/LV ( IFL ) , with 8 year follow-up .